Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Current Liabilities (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Total Current Liabilities for 11 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 34.36% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 34.36% year-over-year, with the annual reading at $2.3 million for FY2025, 34.36% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $2.3 million at Marker Therapeutics, down from $3.3 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $13.5 million in Q2 2022, with the low at $2.0 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $5.5 million, with a median of $3.8 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities surged 138.07% in 2022, then plummeted 78.32% in 2023.
  • Over 5 years, Total Current Liabilities stood at $12.9 million in 2021, then tumbled by 39.68% to $7.8 million in 2022, then plummeted by 60.49% to $3.1 million in 2023, then rose by 12.67% to $3.5 million in 2024, then tumbled by 34.36% to $2.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.3 million, $3.3 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.